August 19, 2024

Subcutaneous versus intravenous infliximab therapy – a real-world study: toward higher drug concentrations

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Recently, a formula of subcutaneous infliximab (SC-IFX) has been approved for inflammatory bowel disease (IBD), demonstrating a better pharmacokinetic and immunogenic profiles, compared to intravenous infliximab (IV-IFX), with similar efficacy and safety.

Me gusta

Guardar

Cite This Study

Ferreira et al. (Mon,) studied this question.

synapsesocial.com/papers/68e5bc3fb6db6435875549fd https://doi.org/https://doi.org/10.1097/meg.0000000000002835

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Long‐term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The <scp>REMSWITCH‐LT</scp> study2023 · 30 citations
2Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study2022 · 89 citations
3Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases2018 · 599 citations
4Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial2002 · 4,164 citations
5From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative2021 · 32 citations

Me gusta

Guardar